Fig. 8: Inhibition of SLC7A11 attenuates microglial activation and improves motor dysfunction in LPS-injected mice.

A Experimental schedule. B–E Quantification of latency to fall in rotarod test, total distance and immobility time in OFT, time on the pole in pole test of Control, LPS (SN injection), SAS, and SAS + LPS (SN injection) mice. N = 7 per group. F Representative confocal images staining of IBA1 (green) and SLC7A11 (red) in the SN of Control, LPS (SN injection), SAS, and SAS + LPS (SN injection) mice. Scale bar, 50 µm. G Quantification of the ratio of SLC7A11⁺IBA1⁺ area to IBA1⁺ cells area. N = 3 per group. H Representative images staining of IBA1 (green) and TH (red) in the SN of Control, LPS (SN injection), SAS, and SAS + LPS (SN injection) mice. Scale bar, 200 µm. I and J Quantification of TH⁺ cells and IBA1⁺ cells. N = 4 per group. K Representative images staining of IBA1 (green) and CD86 (red) in the SN of Control, LPS (SN injection), SAS, and SAS + LPS (SN injection) mice. Scale bar, 100 µm. L Quantification of the ratio of CD86⁺IBA1⁺ area to IBA1⁺ cells area. N = 4 per group. M–Q Il1b, Nlrp3, Cd80, Cd 86 and Cd206 mRNA expression in the SN tissues of Control, LPS (SN injection), SAS, and SAS + LPS (SN injection) mice. N = 4 per group. Data are shown as the mean ± SEM. Data were analyzed with one-way ANOVA followed by Tukey’s multiple comparisons test. Compared to PBS group, ^#P < 0.05, ^##P < 0.01, ^###P < 0.001, ^####P < 0.0001; compared to LPS (SN injection) group, ^*P < 0.05, ^**P < 0.01, ^***P < 0.001, ^****P < 0.0001.